One of Israel's leading importers of medicines and medical equipment, Promedico, has acquired Jacobsohn, another leading importer, for an undisclosed sum. It is understood that Promedico has plans to set up a manufacturing facility near the city of Haifa.
Promedico represents Zyma as well as a number of major US multinational drugmakers, whereas Jacobsohn has the Ciba-Geigy agency. Both companies have had substantial market shares for many years, but increasing generic competition, import substitution, a slow-down in product pipelines and uncertainty regarding the impact of National Health Insurance appear to be the main factors behind this consolidation of the importing sector. Imports account for about 45% of the total pharmaceutical market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze